•  
  •  
 

Abstract

Objective: This study aims to assess structural, refractive, and biometric outcomes and safety of intravitreal ranibizumab (IVR) for treatment requiring retinopathy of prematurity (ROP) 1-year post-IVR. Background: IVR has been proposed as alternative to conventional laser photocoagulation for treatment requiring ROP in different zones to achieve better structural and functional outcomes. Methods: A prospective case series conducted in in Menoufia university hospitals, Menoufia governorate, Egypt during the period from January 2021 to December 2022. Premature infants who met the eligibility criteria with type 1 pre-threshold ROP, threshold ROP and Aggressive-ROP (A-ROP) received IVR of 0.25mg (0.025 ml). Postoperatively, patients were reviewed to evaluate initial response, reactivation, and eventual structural and functional outcomes at 1-year post-IVR. Results: Thirty-two eyes of 19 infants received IVR with 90.26%, 3.125%, and 6.25% showing initial regression, persistence, and progression respectively. Reactivation occurred in 18.75% of eyes yet only one eye required retreatment. At1-year post-IVR, treatment was labelled successful in 87.5% of eyes with 78.57% showing full retinal vascularization. Mean spherical equivalent (SE) and axial length of treated patients were -0.98±1.036D and 20.75±0.57mm respectively with no significant difference in the different zones (p=0.069, and p=0.886 respectively). No eye showed high myopia (≥5D), nystagmus, strabismus, nor glaucoma. Conclusion: IVR is proven to be effective for management of treatment requiring ROP showing good structural and functional outcomes at 1-year follow up in different zones with good safety profile. Despite the high rate of reactivation, only limited number requires retreatment with final good results.

Subject Area

Ophthalmology

Article Type

Original Study

Download

Share

COinS